IXICO plc Conference attendance and presentations
01 March 2021
("IXICO" or the "Company")
Conference attendance and presentations
IXICO virtually attends AD/PD 2021 Conference
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , announces it will be presenting at the
upcoming virtual AD/PD 2021 conference taking place virtually on
9-14 March 2021. AD/PD 2021, the 15th International Conference on
Alzheimer's and Parkinson's Diseases and related neurological
disorders, is one of the most prestigious in the year and IXICO
welcomes the opportunity to present.
The following presentation and poster presentations will be made
across the week:
-- Michael Reinwald, PhD, Associate Research Engineer at IXICO
plc, will give a pre-recorded oral presentation, titled: " A
deep-learning based framework for brain-atrophy measurement"
-- Jack Weatheritt, PhD, Senior Research Engineer at IXICO plc,
will present the poster: "Automatic segmentation using deep
learning for the hippocampus"
-- Luis Peraza, PhD, Research Engineer at IXICO plc, will present two posters:
1) "An adaptive step detection algorithm for waist-worn wearable
devices: a feasibility study in older adults"
2) "Added value of wearable sensors for fall risk assessment in
an older adult group"
The conference attracts international medical and scientific
professionals worldwide to focus on the mechanisms of disease,
prevention and therapy within the neurodegenerative disease space.
More information on the conference can be found here: Welcome
Message - AD/PD(TM) 2021 | March 9 - 14, 2021 | Virtual Conference
Robin Wolz, Chief Scientific Officer at IXICO, commented: "We
are excited about the opportunity to provide an update on various
R&D activities at the AD/PD conference. Deep learning
approaches in combination with well curated, high-quality data
enable us to develop tools that can extract clinically meaningful
insights that were previously not detectable and at a processing
speed previously unthinkable. We look forward to sharing an update
on how this technology impacts our ability to interpret both
imaging and wearables data."
The video presentation and related posters will be available on
the Company's website after the event has concluded, here: Webinars
>> IXICO and Publications >> IXICO .
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Michael F Johnson / Russell Kerr
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
March 01, 2021 02:00 ET (07:00 GMT)